A randomized controlled protocol on the effect of acupuncture combined with chinese herbal medicine on the cardiac function and quality of life in patients with chronic aplastic anemia

注册号:

Registration number:

ITMCTR2100005274

最近更新日期:

Date of Last Refreshed on:

2021-09-04

注册时间:

Date of Registration:

2021-09-04

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

针药结合干预慢性再生障碍性贫血的临床研究

Public title:

A randomized controlled protocol on the effect of acupuncture combined with chinese herbal medicine on the cardiac function and quality of life in patients with chronic aplastic anemia

注册题目简写:

English Acronym:

研究课题的正式科学名称:

针药结合干预慢性再生障碍性贫血的临床研究

Scientific title:

A randomized controlled protocol on the effect of acupuncture combined with chinese herbal medicine on the cardiac function and quality of life in patients with chronic aplastic anemia

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR2100050819 ; ChiMCTR2100005274

申请注册联系人:

潘一鸣

研究负责人:

潘一鸣

Applicant:

Yi-ming Pan

Study leader:

Yi-ming Pan

申请注册联系人电话:

Applicant telephone:

84012662

研究负责人电话:

Study leader's telephone:

84012662

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

pym_bucm@sina.com

研究负责人电子邮件:

Study leader's E-mail:

pym_bucm@sina.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

中国北京市东城区海运仓5号

研究负责人通讯地址:

中国北京市东城区海运仓5号

Applicant address:

Dongzhimen Hospital,Beijing University of Chinese Medicine, No. 5, Haiyuncang, Dongcheng District, Beijing, 100700, China

Study leader's address:

Dongzhimen Hospital,Beijing University of Chinese Medicine, No. 5, Haiyuncang, Dongcheng District, Beijing, 100700, China

申请注册联系人邮政编码:

Applicant postcode:

100700

研究负责人邮政编码:

Study leader's postcode:

100700

申请人所在单位:

北京中医药大学附属东直门医院

Applicant's institution:

Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing China

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

Name of the ethic committee:

伦理委员会批准日期:

Date of approved by ethic committee:

2013/8/26 0:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

北京中医药大学附属东直门医院

Primary sponsor:

Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine

研究实施负责(组长)单位地址:

中国北京市东城区海运仓5号北京中医药大学附属东直门医院

Primary sponsor's address:

Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, No. 5, Haiyuncang, Dongcheng District, Beijing, 100700, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

北京中医药大学附属东直门医院

具体地址:

中国北京市东城区海运仓5号

Institution
hospital:

Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicin

Address:

Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, No. 5, Haiyuncang, Dongcheng District, Beijing, 100700, China

经费或物资来源:

北京中医药大学研究生经费资助

Source(s) of funding:

Beijing University of Chinese Medicine Postgraduate Funding

研究疾病:

慢性再生障碍性贫血

研究疾病代码:

Target disease:

Chronic aplastic anemia

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

其它

Others

研究目的:

评估针灸联合中草药治疗慢性再生障碍性贫血的临床疗效,探讨治疗慢性再生障碍性贫血的的简单、安全、简便、有效的新思路。

Objectives of Study:

To evaluate the clinical efficacy of acupuncture combined with Chinese herbal medicine in the treatment of chronic aplastic anemia, and to explore new ideas that are simple, safe, convenient and effective for the treatment of chronic aplastic anemia.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

(1)符合慢性再生障碍性贫血的诊断标准(2)年龄大于14周岁(3)已用其他药物治疗,但已停药2周以上(4)在征得患者极其家属的同意后,自愿加入本课题研究 ;

Inclusion criteria

(1) Meet the diagnostic criteria for chronic aplastic anemia. (2) Age over 14 years old .(3) Have been treated with other drugs, but have been discontinued for more than 2 weeks. (4) After obtaining the consent of the patient and their family members, voluntarily join Research on this subject.

排除标准:

(1)合并其他血液系统疾病; (2)有严重心脑肝肾等器官的严重损伤或处于疾病终末期的病人; (3)妊娠、哺乳期妇女; (4)不能坚持就诊的患者; 上述有一项符合即被排除在外;

Exclusion criteria:

(1) Combined with other blood system diseases; (2) Patients with severe damage to the heart, brain, liver and kidney or in the terminal stage of the disease; (3) Pregnant and lactating women; (4) Patients who cannot insist on medical treatment; One of the above is excluded.

研究实施时间:

Study execute time:

From 2022-02-01

To      2022-12-31

征募观察对象时间:

Recruiting time:

From 2022-03-01

To      2022-10-31

干预措施:

Interventions:

组别:

对照组

样本量:

30

Group:

Control group

Sample size:

干预措施:

西医常规治疗

干预措施代码:

Intervention:

Western medicine routine treatment

Intervention code:

组别:

针药结合组

样本量:

30

Group:

TCM+A

Sample size:

干预措施:

中药自拟方联合针灸

干预措施代码:

Intervention:

Acupuncture combined with chinese herbal medicine

Intervention code:

组别:

中药组

样本量:

30

Group:

TCM

Sample size:

干预措施:

中药自拟方

干预措施代码:

Intervention:

Traditional Chinese medicine self-proposed

Intervention code:

样本总量 Total sample size : 90

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

北京市

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

北京中医药大学第一临床医院(东直门医院)

单位级别:

三级甲等中医院

Institution/hospital:

The First Clinical Hospital of Beijing University of Chinese Medicine (Dongzhimen Hospital)

Level of the institution:

Grade III A Chinese Medicine Hospital

测量指标:

Outcomes:

指标中文名:

贫血程度分级(血红蛋白含量)

指标类型:

主要指标

Outcome:

Grade of anemia (hemoglobin content)

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

中医证候评分

指标类型:

主要指标

Outcome:

Traditional Chinese medicine syndrome score

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Routine blood analysis

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 15
Min age years
最大 60
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

在整个研究中心按照受试者入选的先后顺序,根据预定的随机方案分配入试验组或对照给。随机方案通过查阅随机对照表或采用计算器或计算机产生。

Randomization Procedure (please state who generates the random number sequence and by what method):

In the entire research center, according to the order of the subjects' selection, they will be assigned to the experimental group or the control group according to the predetermined random scheme. The random scheme is generated by consulting the random comparison table or using a calculator or computer.

盲法:

Blinding:

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

以学术报告的形式

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

n the form of academic reports

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

我们将应用病例记录表、电子采集和管理系统对研究过程中的数据进行采集和管理

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

We will use case records, electronic collection and management systems to collect and manage data during the research process

数据管理委员会:

Data Managemen Committee:

暂未确定

Not yet

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above